摘要
目的评价口服降糖药瑞格列奈治疗2型糖尿病的疗效及安全性。方法检索至今已公开发表的关于比较瑞格列奈和格列齐特治疗2型糖尿病临床效应差异的随机对照试验论文,提取临床效应指标进行Meta分析。结果 7项随机对照试验纳入分析,采用固定效应模型对空腹血糖进行Meta分析,结果显示Z=0.28,P=0.78,WMD=0.04(-0.25,0.34);采用随机效应模型对餐后2小时血糖进行Meta分析,结果显示Z=5.54,P<0.00001,WMD=-1.91(-2.58,-1.23);采用固定效应模型对糖化血红蛋白值进行Meta分析,结果显示Z=1.33,P=0.18,WMD=-0.19(-0.47,-0.09);采用固定效应模型对低血糖进行Meta分析,结果显示Z=3.63,P=0.0003,WMD=0.24(0.11,0.52)。结论瑞格列奈与格列齐特相比,降空腹血糖和糖化血红蛋白值的作用无明显差异,但可使餐后2小时血糖浓度降得更低,同时降低低血糖发生的机会。
Objective To evaluate the efficacy and safety of repaglinide,a kind of oral hypoglycemic agent,in the treatment of type 2 diabetes.Methods Recent published papers that chose randomized comparative trials to distinguish clinical effects between repaglinide and gliclazide were collected for meta-analysis.Results Total seven papers met this requirement and were selected for meta-analysis.When fixed effects model was adopted for fasting plasma glucose（FPG） analysis,results showed that Z=0.28,P= 0.78,WMD=0.04（-0.25,0.34）.When random effects model was adopted for 2h postprandial blood glucose（PBG） analysis,results showed that Z=5.54,P〈0.00001,WMD=-1.91（-2.58,-1.23）.When fixed effects model was adopted for HbAlC analysis,results showed that Z=1.33,P=0.18,WMD=-0.19（-0.47,-0.09）.When fixed effects model was adopted for hypoglycemia analysis,results showed that Z=3.63,P=0.0003,WMD=0.24（0.11,0.52）.Conclusion There is no significant difference between repaglinide and gliclazide in decreasing the levels of FPG and HbAlC.However,repaglinide could further decrease the level of 2 h PBG and prevent against hypoglycemia compared with gliclazide.
出处
《广东药学院学报》
CAS
2012年第6期652-656,共5页
Academic Journal of Guangdong College of Pharmacy
